Replies to post #179664 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Looks like Anavex is filing patents for A2-73 in different indications to extend IP protection if granted. I think that even when the original A2-73 patent for AD expire, newer granted patents in other indication would prevent any threat of generic A2-73.

[XenaLives]

Haven't spent much time on this but so far my key takeaway is they are going for genetic and epigenetic factors.

[Talon38]

Here is the USPTO patent application:

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190022052%22.PGNR.&OS=DN/20190022052&RS=DN/20190022052